|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hillemanns P, Soergel P, Hertel H and
Jentschke M: Epidemiology and early detection of cervical cancer.
Oncol Res Treat. 39:501–506. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cibula D, Raspollini MR, Planchamp F,
Centeno C, Chargari C, Felix A, Fischerova D, Jahnn-Kuch D, Joly F,
Kohler C, et al: ESGO/ESTRO/ESP guidelines for the management of
patients with cervical cancer-Update 2023. Virchows Arch.
482:935–966. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oncology NCPGi, . Cervical Cancer (version
1.2023). 2023.
|
|
5
|
Beckmann MW, Stubs FA, Koch MC, Mallmann
P, Dannecker C, Dietl A, Sevnina A, Mergel F, Lotz L, Hack CC, et
al: Diagnosis, therapy and follow-up of cervical cancer. Guideline
of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL,
May 2021)-Part 1 with recommendations on epidemiology, screening,
diagnostics and therapy. Geburtshilfe Frauenheilkd. 82:139–180.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kusakabe M, Taguchi A, Sone K, Mori M and
Osuga Y: Carcinogenesis and management of human
papillomavirus-associated cervical cancer. Int J Clin Oncol.
28:965–974. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shieh KR, Huang A and Xu Y: Response to
immune checkpoint inhibitor treatment in advanced cervical cancer
and biomarker study. Front Med (Lausanne). 8:6695872021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Felice F, Giudice E, Bolomini G,
Distefano MG, Scambia G, Fagotti A and Marchetti C: Pembrolizumab
for advanced cervical cancer: Safety and efficacy. Expert Rev
Anticancer Ther. 21:221–228. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schmidt MW, Battista MJ, Schmidt M, Garcia
M, Siepmann T, Hasenburg A and Anic K: Efficacy and safety of
immunotherapy for cervical cancer-a systematic review of clinical
trials. Cancers (Basel). 14:4412022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Frenel JS, Le Tourneau C, O'Neil B, Ott
PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas
S, Saraf S, et al: Safety and efficacy of pembrolizumab in
advanced, programmed death ligand 1-positive cervical cancer:
Results from the phase Ib KEYNOTE-028 trial. J Clin Oncol.
35:4035–4041. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oh DY, Algazi A, Capdevila J, Longo F,
Miller W Jr, Bing JT, Bonilla CE, Chung HC, Guren TK, Lin CC, et
al: Efficacy and safety of pembrolizumab monotherapy in patients
with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.
Cancer. 129:1195–1204. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cao J, Zhang C, Jiang GQ, Jin SJ, Wang Q,
Wang AQ and Bai DS: Identification of hepatocellular
carcinoma-related genes associated with macrophage differentiation
based on bioinformatics analyses. Bioengineered. 12:296–309. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xia Y, Rao L, Yao H, Wang Z, Ning P and
Chen X: Engineering macrophages for cancer immunotherapy and drug
delivery. Adv Mater. 32:e20020542020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marques CA, Hahnel PS, Wolfel C, Thaler S,
Huber C, Theobald M and Schuler M: An immune escape screen reveals
Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated
tumor suppression. Blood. 111:1413–1419. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo F, Zhang S, Tripathi P, Mattner J,
Phelan J, Sproles A, Mo J, Wills-Karp M, Grimes HL, Hildeman D and
Zheng Y: Distinct roles of Cdc42 in thymopoiesis and effector and
memory T cell differentiation. PLoS One. 6:e180022011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu J, Shao R, Zhang X, Yao D and Han S:
Serum cell division cycle 42 in advanced hepatocellular carcinoma
patients: Linkage with clinical characteristics and immune
checkpoint inhibitor-related treatment outcomes. Clin Res Hepatol
Gastroenterol. 47:1021492023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang L, Shen Y and Wang Y: Vertical level
of blood cell division cycle 42 predicts response and survival
benefits to PD-1 inhibitor-based regimen in metastatic colorectal
cancer patients. Scand J Clin Lab Invest. 83:103–110. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bergerot CD, Philip EJ, Bergerot PG, Hsu
J, Dizman N, Salgia M, Salgia N, Vaishampayan U, Battle D, Loscalzo
M, et al: Discrepancies between genitourinary cancer patients' and
clinicians' characterization of the Eastern Cooperative Oncology
Group performance status. Cancer. 127:354–358. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schwartz LH, Litiere S, de Vries E, Ford
R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J,
et al: RECIST 1.1-Update and clarification: From the RECIST
committee. Eur J Cancer. 62:132–137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saleh M, Virarkar M, Bhosale P, El Sherif
S, Javadi S and Faria SC: Endometrial cancer, the current
international federation of gynecology and obstetrics staging
system, and the role of imaging. J Comput Assist Tomogr.
44:714–729. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Robert ME, Ruschoff J, Jasani B, Graham
RP, Badve SS, Rodriguez-Justo M, Kodach LL, Srivastava A, Wang HL,
Tang LH, et al: High interobserver variability among pathologists
using combined positive score to evaluate PD-L1 expression in
gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Mod Pathol. 36:1001542023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang B, Zhong X, Sauane M, Zhao Y and
Zheng ZL: Modulation of the Pol II CTD phosphorylation code by Rac1
and Cdc42 small GTPases in cultured human cancer cells and its
implication for developing a synthetic-lethal cancer therapy.
Cells. 9:6212020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong Z, Yu C, Rezhiya K, Gulijiahan A and
Wang X: Downregulation of miR-146a promotes tumorigenesis of
cervical cancer stem cells via VEGF/CDC42/PAK1 signaling pathway.
Artif Cells Nanomed Biotechnol. 47:3711–3719. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun X, Zhou L, Wang X, Li Y, Liu X, Chen
Y, Zhong Z and Chen J: FYCO1 regulates migration, invasion, and
invadopodia formation in HeLa cells through CDC42/N-WASP/Arp2/3
signaling pathway. Biochem Cell Biol. 100:458–472. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li X, Chen B, Huang A, Ren C, Wang L, Zhu
T, Xiong J, Ding W and Wang H: LncRNA HCP5 enhances the
proliferation and migration of cervical cancer via
miR-216a-5p/CDC42 axis. J Cancer. 13:1882–1894. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen R and Zhang L: MiR-29a inhibits cell
proliferation and migration by targeting the CDC42/PAK1 signaling
pathway in cervical cancer. Anticancer Drugs. 30:579–587. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Serrano-Pertierra E, Cernuda-Morollon E
and Lopez-Larrea C: NKG2D- and CD28-mediated costimulation regulate
CD8+ T cell chemotaxis through different mechanisms: The role of
Cdc42/N-WASp. J Leukoc Biol. 95:487–495. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
An J, Li X, Wang J, Zhu L, An R, Jiang K,
Huang Y, Wang K, Li G, Wang C, et al: Efficacy and safety of
serplulimab plus nab-paclitaxel in previously treated patients with
PD-L1-positive advanced cervical cancer: A phase II, single-arm
study. Front Immunol. 14:11422562023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tewari KS, Monk BJ, Vergote I, Miller A,
de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouelian V, Lorusso D,
et al: Survival with cemiplimab in recurrent cervical cancer. N
Engl J Med. 386:544–555. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Monk BJ, Tewari KS, Dubot C, Caceres MV,
Hasegawa K, Shapira-Frommer R, Salman P, Yanez E, Gumus M, de
Mendoza MO, et al: Health-related quality of life with
pembrolizumab or placebo plus chemotherapy with or without
bevacizumab for persistent, recurrent, or metastatic cervical
cancer (KEYNOTE-826): A randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet Oncol. 24:392–402. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
O'Malley DM, Oaknin A, Monk BJ, Selle F,
Rojas C, Gladieff L, Berton D, Leary A, Moore KN, Estevez-Diz MDP,
et al: Phase II study of the safety and efficacy of the anti-PD-1
antibody balstilimab in patients with recurrent and/or metastatic
cervical cancer. Gynecol Oncol. 163:274–280. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Laletin V, Bernard PL, da Silva CS,
Guittard G and Nunes JA: Negative intracellular regulators of
T-cell receptor (TCR) signaling as potential antitumor
immunotherapy targets. J Immunother Cancer. 11:e0058452023.
View Article : Google Scholar : PubMed/NCBI
|
